Synopsys Inc
Change company Symbol lookup
Select an option...
SNPS Synopsys Inc
BAC Bank of America Corp
SU Suncor Energy Inc
USOI Credit Suisse X-Links Crude Oil Shares Covered Call ETNs
GE General Electric Co
HLNE Hamilton Lane Inc
HLI Houlihan Lokey Inc
HIG Hartford Financial Services Group Inc
HIBB Hibbett Sports Inc
HHC Howard Hughes Corp
Go

Information Technology : Software | Large Cap Growth
Company profile

Synopsys, Inc. provides software, intellectual property (IP) and services. The Company supplies the electronic design automation (EDA) software that engineers use to design and test integrated circuits, also known as chips. It also offers IP products, which are pre-designed circuits that engineers use as components of larger chip designs rather than designing those circuits themselves. It provides software and hardware used to develop the electronic systems that incorporate chips and the software that runs on them. It provides technical services to support its solutions and help its customers develop chips and electronic systems. It is also a provider of software tools that developers use to develop software code in a range of industries, including electronics, financial services, energy, and industrials. It offers products and services in four categories: core EDA; IP, Systems and Software Integrity; Manufacturing Solutions, and Professional Services and Other.

Closing Price
$198.79
Day's Change
-3.47 (-1.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
202.22
Day's Low
196.14
Volume
(Below Average)
Volume:
518,301

10-day average volume:
597,641
518,301

Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th

10:00 am ET June 12, 2020 (BusinessWire) Print

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Thursday, June 18, 2020 at 11:30 a.m. EDT. The purpose of the call is to review the data presented at the American Diabetes Association 80th Scientific Sessions held on June 12-16, 2020 on our oral small molecule GLP-1R agonist (PF-06882961) and at the World Federation of Hemophilia Virtual Summit held on June 14-19, 2020 on the Alta Hemophilia A Gene Therapy Study (partnered with Sangamo Therapeutics, Inc.).

To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to pre-register in advance of the conference call.

You can also listen to the conference call by dialing either (833) 713-5203 in the United States and Canada or (830) 213-7598 outside of the United States and Canada. The password is "Pfizer2020".

Visitors will be able to view and listen to an archived copy of the webcast at www.pfizer.com/investors.

About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcast may include forward-looking statements about, among other things, Pfizer's oral small molecule GLP-1R agonist (PF-06882961) program and Alta Hemophilia A Gene Therapy Study, including their potential benefits, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200612005026/en/

SOURCE: Pfizer Inc.

Media Relations:


Steven Danehy 
+1 (978) 273-3946 
Steven.Danehy@Pfizer.com 


Investor Relations:


Bryan Dunn 
+1 (212) 733-8917 
Bryan.Dunn@Pfizer.com

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.